ETHERNA
LIVE

Serial Number

97728325

Owner

eTheRNA immunotherapies NV

Attorney

Cheryl L. Burbach

First Use Date

Oct 30, 2013

Filing Date

Dec 22, 2022

Add to watchlist:

No watchlists yet
View on USPTO

ETHERNA Trademark

Serial Number: 97728325 • Registration: 7634843

ETHERNA is a trademark filed by eTheRNA immunotherapies NV on December 22, 2022. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

eTheRNA immunotherapies NV

Galileilaan 19
Niel 2845 , BE

Entity Type: 99

Trademark Details

Filing Date

December 22, 2022

Registration Date

December 31, 2024

First Use Anywhere

October 30, 2013

First Use in Commerce

October 30, 2013

Published for Opposition

January 2, 2024

Goods & Services

Custom manufacture of pharmaceutical and medical preparations; custom manufacture of mRNA molecules; custom manufacture of mRNA molecules formulated in lipid nanoparticles; custom manufacture of mRNA for use in vaccines, cell therapy, gene editing, protein replacement, and antibodies; provision of information, advice and consultancy services relating to all of the aforesaid

Vaccines; vaccine adjuvants; medical, biological, and pharmaceutical preparations for medical use, namely, preparations containing messenger RNA for preventing and treating viruses, medical disorders, and diseases, namely, viral infections, bacterial infections, cancer, viral, bacterial, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; mRNA-based therapeutics and therapeutic agents for in prevention and treatment of viruses, medical disorders, and diseases, namely, viral infections, bacterial infections, cancer, viral, bacterial, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; lipid nanoparticles for pharmaceutical, medical or diagnostic purposes for preventing and treating viruses, medical disorders, and diseases, namely, viral infections, bacterial infections, cancer, viral, bacterial, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; drug carriers for medical use, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals; lipid nanoparticles for drug delivery sold as an integral component of drugs in the nature of pharmaceutical preparations for preventing and treating viruses, medical disorders, and diseases, viral infections, bacterial infections, cancer, viral, bacterial, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; pharmaceutical preparations, namely, messenger RNA and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells for preventing and treating viruses, medical disorders, and diseases, namely, viral infections, bacterial infections, cancer, viral, bacterial, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders

Biological preparations for scientific and research purposes for boosting cells in the immune system for improved therapies; biological preparations for scientific and research purposes, namely, a mRNA-based composition for enhancing immunities; biological preparations in the nature of genetically modified cells and vectors for scientific and research purposes; biological and chemical reagents including complexes of these molecules for research purposes, for clinical research, clinical chemistry, clinical trials, scientific research, medical research, laboratory research, and for industrial use, namely, for use in the manufacture of pharmaceuticals

Scientific research and development; pharmaceutical research and development services; medical research and development services; scientific, pharmaceutical, and medical research and development in the field of mRNA therapeutics; scientific, pharmaceutical, and medical research and development in the field of proprietary lipids and lipid nanoparticle formulations for the delivery of mRNA therapeutics for the treatment of various medical disorders, cancer, and infectious diseases

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Dec 31, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Dec 31, 2024 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Dec 10, 2024 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Dec 10, 2024 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Oct 22, 2024 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Oct 22, 2024 AITU
USE AMENDMENT FILED
Aug 16, 2024 IUAF
TEAS STATEMENT OF USE RECEIVED
Aug 16, 2024 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 13, 2024 EXRA
SOU EXTENSION 1 GRANTED
Aug 13, 2024 EX1G
SOU EXTENSION 1 FILED
Aug 13, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Aug 13, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 27, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 2, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jan 2, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 13, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 28, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 26, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 26, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 26, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 6, 2023 GNRN
NON-FINAL ACTION E-MAILED
Oct 6, 2023 GNRT
NON-FINAL ACTION WRITTEN
Oct 6, 2023 CNRT
ASSIGNED TO EXAMINER
Sep 22, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 19, 2023 NWOS
NEW APPLICATION ENTERED
Dec 26, 2022 NWAP